Efficacy and Tolerability of Ublituximab after Transitioning from a Different Disease-Modifying Therapy: Updates from the ENHANCE Study By admin / 09/18/2024
BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated with BRIUMVI (ublituximab-xiiy) By admin / 05/30/2024
A Post-Marketing Study Evaluating the Presence and Concentration of BRIUMVI®(ublituximab-xiiy) in Breastmilk (PROVIDE) By admin / 05/30/2024
Early Initiation of Ublituximab Treatment is Associated with Improved Disability Outcomes Among Treatment-Naïve Participants in ULTIMATE I and II By admin / 04/17/2024
Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies By admin / 04/17/2024
MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide By admin / 04/14/2024
Evaluating the Maintenance of Efficacy and Tolerability of Transitioning from IV Anti-CD20 Therapy to Ublituximab: ENHANCE Study Interim Data By admin / 02/29/2024
MS Relapse Redefined: Addressing the Radiological/Pseudoexacerbation Paradox with High Efficacy Therapy in the ULTIMATE I and II Trials By admin / 02/29/2024
Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies By admin / 10/12/2023
Evaluating the Maintenance of Efficacy and Tolerability when Transitioning from IV anti-CD20 Therapy to Ublituximab: ENHANCE Study Design, Patient Demographics and Preliminary Data By admin / 10/11/2023
